Comparative Pharmacology
Head-to-head clinical analysis: DEFLAZACORT versus HYDELTRASOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEFLAZACORT versus HYDELTRASOL.
DEFLAZACORT vs HYDELTRASOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deflazacort is a glucocorticoid prodrug that is metabolized to its active form, 21-desacetyldeflazacort. It binds to glucocorticoid receptors, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses multiple inflammatory cytokines and induces lipocortin synthesis.
6-90 mg orally once daily; initial dose typically 6-30 mg/day, maintenance as lowest effective dose; taper gradually upon discontinuation.
Intravenous: Initial dose 100-250 mg, then repeat every 10-30 minutes as needed. Intramuscular: 100-250 mg every 10-30 minutes. Intra-articular: 10-40 mg per joint every 1-2 weeks.
None Documented
None Documented
Clinical Note
moderateDeflazacort + Gatifloxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Gatifloxacin."
Clinical Note
moderateDeflazacort + Rosoxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Rosoxacin."
Clinical Note
moderateDeflazacort + Levofloxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Levofloxacin."
Clinical Note
moderateDeflazacort + Trovafloxacin
Terminal half-life of the active metabolite Δ6-deflazacort is 1.1–1.9 hours; parent drug half-life is approximately 1–2 hours. Clinical glucocorticoid effect persists for 12–24 hours due to receptor binding.
Terminal half-life ~2-3 hours; clinically, adrenal suppression may persist >24h.
Renal (approximately 70% as metabolites, <5% unchanged); biliary/fecal (approximately 30%)
Renally eliminated: ~80% as metabolites, <10% unchanged. Biliary/fecal: minor.
Category C
Category C
Corticosteroid
Corticosteroid
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Trovafloxacin."